ANIMATION

Gleevec (imatinib) MOA

Share this article with:

Kit is a receptor tyrosine kinase that activates of a number of pathways that direct cell proliferation, survival, and apoptosis. Mutations in Kit that result in constitutive oligomerization in the absence of ligand can drive continuous oncogenic signaling. The majority of gastrointestinal stromal tumor (GIST) cells have been found to present with overactive Kit signaling. Gleevec, or Glivec (imatinib mesylate) competitively binds to the ATP binding pocket of both active and inactive Kit, preventing downstream signaling. Kit inhibition by imatinib may induce both apoptosis and quiescence in KIT+ GIST cells.

Share It:
Contact XVIVO

Client


Novartis

Through their creative prowess and technical mastery, XVIVO is defining and redefining the very frontier of scientific animation. As science and medicine explore increasingly remote realms, their work provides a vital link allowing researchers and the general public to grasp visually an astonishing landscape of new possibilities.

Brian Greene, Professor Mathematics & Physics, Columbia University